Workflow
数字化X线探测器
icon
Search documents
奕瑞科技涨2.03%,成交额1.03亿元,主力资金净流出186.58万元
Xin Lang Cai Jing· 2025-09-30 03:20
Company Overview - Yirui Technology has seen a stock price increase of 71.14% year-to-date, with a 3.53% rise in the last five trading days, 2.09% in the last 20 days, and 31.42% in the last 60 days [2] - The company specializes in the research, production, sales, and service of digital X-ray detectors, with its main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [2] - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, a year-on-year increase of 3.94%, and a net profit attributable to shareholders of 335 million yuan, up 8.82% year-on-year [2] Market Performance - As of September 30, Yirui Technology's stock price was 115.65 yuan per share, with a market capitalization of 23.155 billion yuan [1] - The trading volume was 1.03 billion yuan, with a turnover rate of 0.45% [1] - The net outflow of main funds was 1.8658 million yuan, with large orders accounting for 23.21% of purchases and 24.90% of sales [1] Shareholder Information - Yirui Technology has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up 15.02% [2][3] - The ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder [3]
奕瑞科技股价涨5.15%,汇添富基金旗下1只基金重仓,持有99万股浮盈赚取569.22万元
Xin Lang Cai Jing· 2025-09-24 06:06
9月24日,奕瑞科技涨5.15%,截至发稿,报117.46元/股,成交3.53亿元,换手率1.55%,总市值235.18 亿元。 资料显示,奕瑞电子科技集团股份有限公司位于上海市浦东新区环桥路999号,成立日期2011年3月7 日,上市日期2020年9月18日,公司主营业务涉及数字化X线探测器研发、生产、销售与服务。主营业 务收入构成为:探测器销售81.21%,核心部件销售7.66%,解决方案/技术服务收入5.89%,配件销售 4.57%,租赁收入0.66%。 从基金十大重仓股角度 数据显示,汇添富基金旗下1只基金重仓奕瑞科技。汇添富民营活力混合(470009)二季度持有股数99 万股,占基金净值比例为3.63%,位居第四大重仓股。根据测算,今日浮盈赚取约569.22万元。 汇添富民营活力混合(470009)成立日期2010年5月5日,最新规模23.92亿。今年以来收益55.49%,同 类排名761/8173;近一年收益91.48%,同类排名859/7996;成立以来收益703.93%。 汇添富民营活力混合(470009)基金经理为马翔。 截至发稿,马翔累计任职时间9年200天,现任基金资产总规模107.26 ...
奕瑞科技跌2.02%,成交额2.48亿元,主力资金净流出679.79万元
Xin Lang Cai Jing· 2025-09-18 06:02
9月18日,奕瑞科技盘中下跌2.02%,截至13:46,报111.70元/股,成交2.48亿元,换手率1.09%,总市值 223.64亿元。 奕瑞科技所属申万行业为:医药生物-医疗器械-医疗设备。所属概念板块包括:口腔医疗、专精特新、 融资融券、中盘、增持回购等。 截至6月30日,奕瑞科技股东户数6990.00,较上期增加21.67%;人均流通股28643股,较上期增加 15.02%。2025年1月-6月,奕瑞科技实现营业收入10.67亿元,同比增长3.94%;归母净利润3.35亿元,同 比增长8.82%。 分红方面,奕瑞科技A股上市后累计派现7.89亿元。近三年,累计派现5.57亿元。 机构持仓方面,截止2025年6月30日,奕瑞科技十大流通股东中,华宝中证医疗ETF(512170)位居第 九大流通股东,持股392.60万股,为新进股东。景顺长城新能源产业股票A类(011328)退出十大流通 股东之列。 责任编辑:小浪快报 资金流向方面,主力资金净流出679.79万元,特大单买入1264.27万元,占比5.10%,卖出3179.83万元, 占比12.83%;大单买入5865.77万元,占比23.67%,卖出 ...
奕瑞科技跌2.02%,成交额1.24亿元,主力资金净流出260.66万元
Xin Lang Cai Jing· 2025-09-17 02:25
Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 789 million yuan, with 557 million yuan distributed over the past three years [3] Stock Market Activity - On September 17, Yirui Technology's stock price decreased by 2.02%, trading at 112.33 yuan per share, with a total market capitalization of 22.491 billion yuan [1] - The stock has seen a year-to-date increase of 66.23%, with a 1.95% rise over the last five trading days, 1.98% over the last twenty days, and 24.88% over the last sixty days [1] - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per shareholder, up 15.02% [2] Institutional Holdings - As of June 30, 2025, the ninth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 3.926 million shares as a new shareholder, while the Invesco Great Wall New Energy Industry Stock A Class has exited the top ten circulating shareholders [3]
奕瑞科技跌2.05%,成交额6105.58万元,主力资金净流出494.04万元
Xin Lang Cai Jing· 2025-09-15 02:09
Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service revenue (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] Stock Performance - On September 15, Yirui Technology's stock price decreased by 2.05%, trading at 109.20 yuan per share, with a market capitalization of 21.864 billion yuan [1] - The stock has seen a year-to-date increase of 61.60%, a decline of 7.84% over the last five trading days, a slight increase of 1.10% over the last 20 days, and a rise of 24.67% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up by 15.02% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF is a new entrant holding 3.926 million shares, while Jingshun Changcheng New Energy Industry Stock A has exited the list [3] Market Position - Yirui Technology operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as oral healthcare, specialized and innovative enterprises, mid-cap stocks, margin financing, and share buybacks [1]
奕瑞科技:9月12日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-12 13:28
Group 1 - The company, Yirui Technology, announced the convening of its 18th meeting of the third board of directors on September 12, 2025, to review proposals including the authorization for the issuance of A-shares to specific targets for the year 2024 [1] - For the fiscal year 2024, the revenue composition of Yirui Technology is as follows: digital X-ray detectors account for 93.53% and other businesses account for 6.47% [1] - As of the report date, Yirui Technology has a market capitalization of 22.3 billion yuan [1]
奕瑞科技股价跌5.03%,天弘基金旗下1只基金重仓,持有18.3万股浮亏损失107.58万元
Xin Lang Cai Jing· 2025-09-04 06:33
Company Overview - Yirui Technology Co., Ltd. is located at 999 Huanqiao Road, Pudong New District, Shanghai, established on March 7, 2011, and listed on September 18, 2020 [1] - The company's main business involves the research, production, sales, and service of digital X-ray detectors [1] Revenue Composition - The revenue composition of Yirui Technology is as follows: - Detector sales account for 81.21% - Core component sales contribute 7.66% - Solutions/technical services generate 5.89% - Accessory sales make up 4.57% - Rental income is 0.66% [1] Stock Performance - On September 4, Yirui Technology's stock fell by 5.03%, closing at 111.00 CNY per share, with a trading volume of 257 million CNY and a turnover rate of 1.13%, resulting in a total market capitalization of 22.224 billion CNY [1] Fund Holdings - Tianhong Fund has a significant holding in Yirui Technology, with the Tianhong CSI Pharmaceutical 100A fund (001550) holding 183,000 shares, representing 1.09% of the fund's net value, making it the ninth-largest holding [2] - The Tianhong CSI Pharmaceutical 100A fund was established on June 30, 2015, with a latest scale of 755 million CNY [2] Fund Performance - The Tianhong CSI Pharmaceutical 100A fund has achieved a year-to-date return of 18.58%, ranking 2307 out of 4222 in its category, and a one-year return of 32.54%, ranking 2866 out of 3789 [2]
奕瑞科技: 奕瑞电子科技集团股份有限公司2024年度向特定对象发行A股股票募集说明书
Zheng Quan Zhi Xing· 2025-09-03 14:13
Core Viewpoint - iRay Group is planning to issue shares to specific investors, with the aim of raising funds for the construction of X-ray vacuum devices and comprehensive solutions, totaling an investment of approximately 1.56 billion yuan, of which 1.17 billion yuan will be funded through this issuance [6][7]. Summary by Sections Company Overview - iRay Group is located at 999 Huanqiao Road, Pudong New District, Shanghai, and is involved in the development and manufacturing of X-ray imaging technology [1]. Issuance Details - The company plans to issue no more than 30,032,755 shares, which is capped at 15% of the total share capital as of June 30, 2025 [6]. - The issuance will be priced at 80% of the average trading price over the 20 trading days prior to the pricing date [3][4]. Use of Proceeds - The net proceeds from the issuance will be allocated to the X-ray vacuum devices and comprehensive solutions project, which has a total investment of 1.56 billion yuan [6][7]. - The company may adjust the investment amounts based on project progress and funding needs [6]. Risk Factors - The company highlights several risks, including the potential inability to absorb new production capacity, insufficient technical development for new products, and increased depreciation from new long-term assets [7][10]. - The company also notes the risk of rapid growth in accounts receivable, which could impact cash flow and operational efficiency [9][11]. Financial Health - As of the end of the reporting period, the company's asset-liability ratio was 50.54%, indicating a significant level of debt [11]. - The company has raised funds through convertible bonds and bank loans to finance various projects, which may lead to further increases in debt levels [11]. Market Environment - The company operates in a competitive landscape with significant players such as GE Healthcare, Siemens, and Philips, which are also its clients [15][16]. - Geopolitical tensions and trade frictions may pose risks to the company's international operations and competitiveness [12].
奕瑞科技跌2.00%,成交额1.59亿元,主力资金净流出2504.42万元
Xin Lang Zheng Quan· 2025-08-22 03:54
Company Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, is located in Shanghai and specializes in the research, production, sales, and service of digital X-ray detectors [1] - The company's main revenue sources include detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1] Financial Performance - As of June 30, 2025, Yirui Technology reported a revenue of 1.067 billion yuan, representing a year-on-year growth of 3.94%, and a net profit attributable to shareholders of 335 million yuan, with an increase of 8.82% year-on-year [2] - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3] Stock Performance - On August 22, Yirui Technology's stock price decreased by 2.00%, trading at 109.68 yuan per share, with a total market capitalization of 21.96 billion yuan [1] - The stock has seen a year-to-date increase of 62.31%, with a 15.03% rise over the last five trading days, 24.28% over the last 20 days, and 18.99% over the last 60 days [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 21.67% to 6,990, with an average of 28,643 circulating shares per person, up by 15.02% [2] - Among the top ten circulating shareholders, Huabao Zhongzheng Medical ETF is a new entrant holding 3.926 million shares, while Jingshun Changcheng New Energy Industry Stock A has exited the list [3] Market Position - Yirui Technology operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with concepts such as oral medical care, security, mid-cap stocks, and specialized innovation [1]
奕瑞科技2025半年财报:净利3.34亿,持续领跑国产X线探测器赛道
仪器信息网· 2025-08-20 03:55
Core Viewpoint - Yirui Technology reported a steady growth in revenue and net profit for the first half of 2025, with a focus on global market expansion and supply chain digitalization [1][2]. Financial Performance - In the first half of 2025, Yirui Technology achieved revenue of 1.067 billion yuan, a year-on-year increase of 3.94% - The net profit attributable to the parent company was 334 million yuan, reflecting a year-on-year growth of 8.82% [2]. R&D Investment - The company invested 154 million yuan in R&D, accounting for 14.46% of its revenue - Yirui Technology added 70 new intellectual property rights, including 32 invention patents - Key projects include the development of digital X-ray detector technologies and the establishment of an innovation base [3]. Global Market Expansion - Yirui Technology participated in international exhibitions such as CMEF, ECR, and Arab Health to promote new products globally - The company established sales and service platforms in the US, Germany, and South Korea, and expanded teams in emerging markets like Pakistan and Brazil - It became a major supplier of dental CBCT detectors in South Korea and benefited from domestic medical imaging projects [4]. Supply Chain Digitalization - To enhance delivery capabilities, Yirui Technology is advancing automation and digital transformation in production - The company has formed a global layout of "1 headquarters + 6 bases," including facilities in Haining, Taicang, Cleveland, and a new base in Hefei [5].